Background: The aim of our study was to determine the bone turnover markers in patients with spinal cord injury (SCI) with and without heterotopic ossification.
Methods: Markers of bone formation (Osteocalcin, serum type 1 procollagen (N-terminal) (tP1NP)) and bone resorption (serum collagen type 1 cross-linked C-telopeptide (β-CTx)) were determined by the electrochemiluminiscence immunoassay ECLIA for Elecsys user cobas immunoassay analyzer. In the study were included 23 patients with spinal cord injury first group (average age 26.8±3.9, duration of spinal cord injury from 3 to 12 months) and 23 healthy peoples appropriate age and gender (average age 30.6±6.0, years). In the first group included 11 patients with spinal cord injury with the presence of heterotopic ossification subgroup I and 12 patients with spinal cord injury without heterotopic ossification subgroup II.
Results: The results of examination showed that patients of first group had significantly higher bone markers than control group: P1NP (256.7±48.2 ng/ml vs 49.3±5.1 ng/ml, p(0.001), serum β-CTx (1.47±0.23 ng/ml vs 0.45±0.04 ng/ml, p(0.0001), osteocalcin (52.2±9.8 ng/ml vs 24.9±2.08 ng/ml, p(0.001). There were obtained that levels of bone remodeling markers in patients with HO were significantly higher in comparison with patients without HO: P1NP (404.9±84.9 ng/ml vs 133.2±15.7 ng/ml, p(0.001), serum β-CTx (1.75±0.23 ng/ml vs 0.28±0.14 ng/ml, p(0.0001), osteocalcin (87.1±18.9 ng/ml vs 29.4±3.7 ng/ml, p(0.001).
Conclusion: The bone formation and bone resorption markers in patient of first group were significantly higher than in healthy individuals of appropriate age. The rate of bone turnover markers in patient with HO was considerably higher than in patient without HO and the process of formation dominated over the resorption in patient with HO.
Disclosure: The authors declared no competing interests.